Small Cell Lung Cancer Irinotecan and CDC2-like Kinase Inhibition Trial (SLICK Trial)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Although small cell lung cancer (SCLC) responds dramatically to initial platinum-based chemotherapy, recurrences are nearly universal. The addition of atezolizumab, an immune checkpoint inhibitor, to front-line chemotherapy has recently demonstrated an improvement in overall survival (OS) in extensive stage SCLC (ES-SCLC). Subsequent lines of therapies are associated with modest efficacy in patients with relapsed disease, and the median overall survival is still 12 to 13 months at best. Cirtuvivint is a small molecule inhibitor of the CDC2-like kinases (CLKs) and dual-specificity tyrosine-regulated kinases (DYRKs); inhibiting CLKs and DYRKs has been shown in preclinical models to cause tumor growth inhibition and sensitize cancer cells to cytotoxic chemotherapy. This study is testing the hypothesis that adding cirtuvivint to chemotherapy in patients with relapsed SCLC will be well tolerated and improve the response rate and progression-free survival (PFS).
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony rozpoznaniem raka płuca małokomórkowego, który powrócił po co najmniej jednym leczeniu chemioterapią na bazie platyny
- •Wiek co najmniej 18 lat
- •Możliwość wykonania codziennych czynności (stan ogólny pozwalający na aktywność)
- •Prawidłowe wyniki badań krwi i funkcji narządów (wątroba, nerki)
- •Dla kobiet i mężczyzn: zgoda na stosowanie antykoncepcji przez cały czas badania i 31 tygodni po jego zakończeniu
- •Zdolność do zrozumienia badania i podpisania zgody
✗ Disqualifies
- •Wcześniejsza nietolerancja lub poważne problemy ze znoszeniem irinotekan
- •Inne aktualnie leczące się nowotwory, które mogłyby wpłynąć na wyniki badania
- •Uczestnictwo w innym badaniu klinicznym z eksperymentalnym lekiem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Washington University School of Medicine
St Louis, United States
Trial contact
Ramaswamy Govindan, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.